American Society of Plastic Surgeons
Member Log In
For Consumers
 

BIA-ALCL Physician Resources


Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) is a rare and highly treatable type of lymphoma that can develop around breast implants. BIA-ALCL occurs most frequently in patients who have breast implants with textured surfaces. The current lifetime risk of BIA-ALCL is estimated to be 1:3817 - 1:30,000 women with textured implants based upon current confirmed cases and textured implant sales data over the past two decades. Since the initial case report in 1996, ASPS now recognizes approximately 195 cases in the US and a total of 521 worldwide as of March 21, 2018.

Most of the patients who have developed BIA-ALCL receive an excellent prognosis following surgical removal of the breast implants and the surrounding scar tissue capsule. Continued follow-up after any breast implant surgery is suggested and important for patient health, but patients who notice pain, lumps, swelling, fluid collections or unexpected changes in breast shape, including asymmetry, should contact their plastic surgeon. In most cases, women diagnosed with BIA-ALCL observed changes in the look or feel of the area surrounding the implant greater than one year after their initial surgical sites were fully healed, and on average eight to ten years after receiving textured implants.

Patients undergoing plastic surgery procedures, aesthetic or reconstructive, should be thoroughly informed of the potential risks and possible complications known to be associated with the procedure, and any device used in that procedure. In the very rare cases where a diagnosis of BIA-ALCL is made, surgical treatment is essential for the management of the disease. Some patients with more advanced disease may require further treatment such as chemotherapy.

FDA updates website on BIA-ALCL

The American Society of Plastic Surgeons (ASPS) would like to make members aware of a recent safety communication update to the Food and Drug Administration (FDA) website regarding breast implant-associated anaplastic large cell lymphoma (BIA-ALCL).

The March 21, 2018 FDA website update acknowledges that while it remains difficult to determine the exact number of BIA-ALCL cases, there have now been 414 medical device reports (MDR) reported to the FDA Manufacturer and User Facility Device Experience (MAUDE) database as of September 30, 2017. Of these MDRs, 272 reports include data related to the implant surface, with 242 identified as textured and 30 smooth. The update also confirms that both silicone gel and saline implants have been reported in cases of BIA-ALCL.

It's important to note that the FDA acknowledges that the MAUDE database may contain limited and potentially inaccurate adverse event reports, and may not represent the true number of U.S. cases, as some entries are duplicates and not all cases are confirmed as ALCL. Though the FDA indicated it has received 30 reports associated with smooth implants there has been no confirmed smooth surface-only case of BIA-ALCL reported. As of March 21, 2018, 195 suspected/confirmed U.S. cases of BIA-ALCL have been reported to the Patient Registry and Outcomes For breast Implants and anaplastic large cell Lymphoma Etiology and Epidemiology (PROFILE) Registry, a joint collaboration between ASPS, PSF, and the FDA.

The FDA's website update confirms previous ASPS communications, noting that BIA-ALCL remains a rare condition that occurs most frequently in patients who have breast implants with textured surfaces. The report also reiterates that patients should discuss with their health-care provider the benefits and risks of textured-surface versus smooth-surface implants. The FDA highlights the World Health Organization recognition of BIA-ALCL, and standardized diagnosis and treatment guidelines established by the National Comprehensive Cancer Network (NCCN).

PROFILE registry.

For more information on BIA-ALCL, visit plasticsurgery.org/alcl or the FDA website.

ASPS is committed to patient safety, advancing quality of care, and practicing medicine based upon the best available scientific evidence. We will continue to monitor and review all new information as it becomes available to keep the plastic surgery community informed.

Please visit the organizations websites for additional info:

Last updated on March 22, 2018. Video published February 23, 2018.